Nautilus Quantifies Tau Proteoforms in Breakthrough Alzheimer’s Study
Event summary
- Nautilus Biotechnology published a study in Nature Methods quantifying 130 tau proteoform groups with single-molecule precision.
- Iterative Mapping resolved proteoforms at 0.1% abundance with <5.5% median coefficient of variation.
- The method revealed ordered, non-random modification patterns in tau proteins linked to Alzheimer’s disease.
- Nautilus plans to expand Iterative Mapping to Parkinson’s disease (α-synuclein) and oncology (AKT1) by mid-2028.
The big picture
Nautilus’ ability to quantify tau proteoforms at scale addresses a critical gap in Alzheimer’s research, where conventional methods obscure functional details. The study validates Iterative Mapping as a potential gold standard for proteome analysis, positioning Nautilus to capture a growing share of the precision medicine market. With plans to expand into Parkinson’s and oncology, the company is betting on a repeatable assay development process to maintain momentum.
What we're watching
- Technology Scalability
- Whether Nautilus can sustain the precision of Iterative Mapping across additional proteoforms beyond tau.
- Clinical Translation
- The pace at which insights from tau proteoforms translate into actionable diagnostics or therapeutics.
- Competitive Positioning
- How Nautilus differentiates its platform against conventional proteomics tools in the race for proteome analysis.
Related topics